B. Frederiksen, P. Brown, S. Dalton, M. Steding-jessen, and M. Osler, Socioeconomic inequalities in prognostic markers of non-Hodgkin lymphoma: Analysis of a national clinical database, European Journal of Cancer, vol.47, issue.6, pp.910-917, 2011.
DOI : 10.1016/j.ejca.2010.11.014

T. Keegan, C. Clarke, E. Chang, S. Shema, and S. Glaser, Disparities in survival after Hodgkin lymphoma: a population-based study, Cancer Causes & Control, vol.105, issue.4, pp.1881-92, 2009.
DOI : 10.1007/s10552-009-9382-3

C. Bray, D. Morrison, and P. Mckay, Socio-economic deprivation and survival of non-Hodgkin lymphoma in Scotland, Leukemia & Lymphoma, vol.34, issue.5, pp.917-940, 2008.
DOI : 10.1161/01.ATV.19.3.485

B. Frederiksen, S. Dalton, M. Osler, M. Steding-jessen, and B. De-nully, Socioeconomic position, treatment, and survival of non-Hodgkin lymphoma in Denmark ??? a nationwide study, British Journal of Cancer, vol.9, issue.5, pp.988-95, 2012.
DOI : 10.1038/bjc.2012.3

T. Keegan, L. Mcclure, J. Foran, and C. Clarke, Improvements in Survival After Follicular Lymphoma by Race/Ethnicity and Socioeconomic Status: A Population-Based Study, Journal of Clinical Oncology, vol.27, issue.18, pp.3044-51, 2009.
DOI : 10.1200/JCO.2008.18.8052

J. Simard, F. Baecklund, E. Chang, E. Baecklund, H. Hjalgrim et al., Lifestyle factors, autoimmune disease and family history in prognosis of non-hodgkin lymphoma overall and subtypes, International Journal of Cancer, vol.70, issue.11
DOI : 10.1002/ijc.27944

M. Wang, K. Burau, S. Fang, H. Wang, and X. Du, Ethnic variations in diagnosis, treatment, socioeconomic status, and survival in a large population-based cohort of elderly patients with non-Hodgkin lymphoma, Cancer, vol.40, issue.11, pp.3231-3272, 2008.
DOI : 10.1002/cncr.23914

I. Kato, J. Booza, W. Quarshie, and K. Schwartz, Persistent socioeconomic inequalities in cancer survival in the United States: 1973?2007 surveillance, epidemiology and end results (SEER) data for breast cancer and non- Hodgkin's lymphoma, J Registry Manag, vol.39, issue.4, pp.158-66, 2012.

S. Kristinsson, Å. Derolf, G. Edgren, P. Dickman, and M. Björkholm, Socioeconomic Differences in Patient Survival Are Increasing for Acute Myeloid Leukemia and Multiple Myeloma in Sweden, Journal of Clinical Oncology, vol.27, issue.12, pp.2073-80, 2009.
DOI : 10.1200/JCO.2008.18.2006

B. Lee, O. Goktepe, K. Hay, J. Connors, L. Sehn et al., Effect of Place of Residence and Treatment on Survival Outcomes in Patients With Diffuse Large B-Cell Lymphoma in British Columbia, The Oncologist, vol.19, issue.3, pp.283-90, 2014.
DOI : 10.1634/theoncologist.2013-0343

A. Olszewski, R. Shrestha, and J. Castillo, Treatment Selection and Outcomes in Early-Stage Classical Hodgkin Lymphoma: Analysis of the National Cancer Data Base, Journal of Clinical Oncology, vol.33, issue.6, pp.625-658, 2015.
DOI : 10.1200/JCO.2014.58.7543

T. Keegan, L. Moy, J. Foran, A. Alizadeh, E. Chang et al., Rituximab use and survival after diffuse large B-cell or follicular lymphoma: a population-based study, Leukemia & Lymphoma, vol.35, issue.1, pp.743-51, 2013.
DOI : 10.1111/j.1365-2141.2007.06943.x

L. Tao, J. Foran, C. Clarke, S. Gomez, and T. Keegan, Socioeconomic disparities in mortality after diffuse large B-cell lymphoma in the modern treatment era, Blood, vol.123, issue.23, pp.3553-62, 2014.
DOI : 10.1182/blood-2013-07-517110

K. Paulson, P. Lambert, C. Bredeson, A. Demers, J. Nowatzki et al., Does location matter? Rural vs urban outcomes after blood and marrow transplantation in a population-based Canadian cohort, Bone Marrow Transplantation, vol.17, issue.7, pp.1167-73, 2010.
DOI : 10.1038/bmt.2008.358

F. Loberiza, A. Cannon, D. Weisenburger, J. Vose, M. Moehr et al., Survival Disparities in Patients With Lymphoma According to Place of Residence and Treatment Provider: A Population-Based Study, Journal of Clinical Oncology, vol.27, issue.32, pp.5376-82, 2009.
DOI : 10.1200/JCO.2009.22.0038

C. Borel, S. Lamy, G. Compaci, C. Récher, P. Jeannot et al., A longitudinal study of non-medical determinants of adherence to R-CHOP therapy for diffuse large B-cell lymphoma: implication for survival, BMC Cancer, vol.64, issue.4, pp.1-11, 2014.
DOI : 10.1136/jech.2008.081117

URL : https://hal.archives-ouvertes.fr/inserm-01264475

T. Hirakawa, H. Yamaguchi, N. Yokose, S. Gomi, K. Inokuchi et al., Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma, Annals of Hematology, vol.24, issue.19, pp.897-904, 2010.
DOI : 10.1007/s00277-010-0956-7

Y. Terada, H. Nakamae, R. Aimoto, H. Kanashima, E. Sakamoto et al., Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma, Journal of Experimental & Clinical Cancer Research, vol.28, issue.1, pp.1-6, 2009.
DOI : 10.1186/1756-9966-28-116

G. Bouche, V. Migeot, S. Mathoulin-pélissier, R. Salamon, and P. Ingrand, Breast cancer surgery: Do all patients want to go to high-volume hospitals?, Surgery, vol.143, issue.6, pp.699-705, 2008.
DOI : 10.1016/j.surg.2008.03.013

M. Pfreundschuh, L. Trümper, A. Österborg, R. Pettengell, M. Trneny et al., CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group, The Lancet Oncology, vol.7, issue.5, pp.379-91, 2006.
DOI : 10.1016/S1470-2045(06)70664-7

B. Coiffier, E. Lepage, J. Brière, R. Herbrecht, H. Tilly et al., CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma, New England Journal of Medicine, vol.346, issue.4, pp.235-277, 2002.
DOI : 10.1056/NEJMoa011795

M. Oken, R. Creech, D. Tormey, J. Horton, T. Davis et al., Toxicity and response criteria of the Eastern Cooperative Oncology Group, AMERICAN JOURNAL OF CLINICAL ONCOLOGY, vol.5, issue.6, pp.649-55, 1982.
DOI : 10.1097/00000421-198212000-00014

J. Blay, F. Gomez, C. Sebban, T. Bachelot, P. Biron et al., The international prognostic index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial, Blood, vol.92, issue.10, pp.3562-3570, 1998.

Z. Zhou, L. Sehn, A. Rademaker, L. Gordon, A. Lacasce et al., An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era, Blood, vol.123, issue.6, pp.837-879, 2014.
DOI : 10.1182/blood-2013-09-524108

O. Fitoussi, K. Belhadj, N. Mounier, M. Parrens, H. Tilly et al., Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA, Haematologica, vol.96, issue.8, pp.1136-1179, 2011.
DOI : 10.3324/haematol.2010.038109

F. Peyrade, F. Jardin, C. Thieblemont, A. Thyss, J. Emile et al., Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial, The Lancet Oncology, vol.12, issue.5, pp.460-468, 2011.
DOI : 10.1016/S1470-2045(11)70069-9

M. Pfreundschuh, J. Schubert, M. Ziepert, R. Schmits, M. Mohren et al., Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60), The Lancet Oncology, vol.9, issue.2, pp.105-121, 2008.
DOI : 10.1016/S1470-2045(08)70002-0

C. Pornet, C. Delpierre, O. Dejardin, P. Grosclaude, L. Launay et al., Construction of an adaptable European transnational ecological deprivation index: the French version, Journal of Epidemiology and Community Health, vol.66, issue.11, pp.982-991, 2012.
DOI : 10.1136/jech-2011-200311

R. Epelbaum, D. Faraggi, Y. Ben-arie, M. Ben-shahar, N. Haim et al., Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables, Cancer, vol.8, issue.6, pp.1124-1133, 1990.
DOI : 10.1002/1097-0142(19900915)66:6<1124::AID-CNCR2820660608>3.0.CO;2-T

R. Development and C. Team, R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2008.

B. Hillner, T. Smith, and C. Desch, Hospital and Physician Volume or Specialization and Outcomes in Cancer Treatment: Importance in Quality of Cancer Care, Journal of Clinical Oncology, vol.18, issue.11, pp.2327-2367, 2000.
DOI : 10.1200/JCO.2000.18.11.2327

M. Cheung, K. Hamilton, R. Sherman, M. Byrne, D. Nguyen et al., Impact of Teaching Facility Status and High-Volume Centers on Outcomes for Lung Cancer Resection: An Examination of 13,469 Surgical Patients, Annals of Surgical Oncology, vol.34, issue.2, pp.3-13, 2009.
DOI : 10.1016/j.ejso.2007.08.002

D. Etzioni, T. Young-fadok, R. Cima, N. Wasif, R. Madoff et al., Patient survival after surgical treatment of rectal cancer: Impact of surgeon and hospital characteristics, Cancer, vol.37, issue.1, pp.2472-81, 2014.
DOI : 10.1002/cncr.28746

W. Cliby, M. Powell, N. Hammadi, L. Chen, P. Miller et al., Ovarian cancer in the United States: Contemporary patterns of care associated with improved survival, Gynecologic Oncology, vol.136, issue.1, pp.11-18, 2014.
DOI : 10.1016/j.ygyno.2014.10.023

F. Vrijens, S. Stordeur, K. Beirens, S. Devriese, E. Van-eycken et al., Effect of hospital volume on processes of care and 5-year survival after breast cancer: A population-based study on 25??000 women, The Breast, vol.21, issue.3, pp.261-267, 2012.
DOI : 10.1016/j.breast.2011.12.002

S. Siesling, V. Tjan-heijnen, M. De-roos, Y. Snel, T. Van-dalen et al., Impact of hospital volume on breast cancer outcome: a population-based study in the Netherlands, Breast Cancer Research and Treatment, vol.248, issue.1, pp.177-84, 2014.
DOI : 10.1007/s10549-014-3075-7

S. Giri, R. Pathak, M. Aryal, P. Karmacharya, V. Bhatt et al., Impact of hospital volume on outcomes of patients undergoing chemotherapy for acute myeloid leukemia: a matched cohort study, Blood, vol.125, issue.21, pp.3359-60, 2015.
DOI : 10.1182/blood-2015-01-625764

G. Compaci, L. Ysebaert, L. Obéric, H. Derumeaux, and G. Laurent, Effectiveness of telephone support during chemotherapy in patients with diffuse large B cell lymphoma: The Ambulatory Medical Assistance (AMA) experience, International Journal of Nursing Studies, vol.48, issue.8
DOI : 10.1016/j.ijnurstu.2011.01.008

E. Wagner, E. Ludman, A. Bowles, E. Penfold, R. Reid et al., Nurse Navigators in Early Cancer Care: A Randomized, Controlled Trial, Journal of Clinical Oncology, vol.32, issue.1, pp.12-20, 2014.
DOI : 10.1200/JCO.2013.51.7359

H. Freeman, B. Muth, and J. Kerner, Expanding access to cancer screening and clinical follow-up among the medically underserved, Cancer Pract, vol.3, issue.1, pp.19-30, 1995.

T. Lee, I. Ko, I. Lee, E. Kim, M. Shin et al., Effects of Nurse Navigators on Health Outcomes of Cancer Patients, Cancer Nursing, vol.34, issue.5, pp.376-84, 2011.
DOI : 10.1097/NCC.0b013e3182025007

L. Mcmullen, Oncology Nurse Navigators and the Continuum of Cancer Care, Seminars in Oncology Nursing, vol.29, issue.2, pp.105-122, 2013.
DOI : 10.1016/j.soncn.2013.02.005

S. Schleifer, S. Bhardwaj, A. Lebovits, J. Tanaka, M. Messe et al., Predictors of physician nonadherence to chemotherapy regimens, Cancer, vol.42, issue.4, pp.945-51, 1991.
DOI : 10.1002/1097-0142(19910215)67:4<945::AID-CNCR2820670415>3.0.CO;2-R

L. Noens, M. Van-lierde, D. Bock, R. Verhoef, G. Zachee et al., Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study, Blood, vol.113, issue.22, pp.5401-5412, 2009.
DOI : 10.1182/blood-2008-12-196543